Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$30.27 - $43.79 $2.27 Million - $3.28 Million
75,000 Added 42.86%
250,000 $8.08 Million
Q4 2023

Feb 14, 2024

BUY
$31.31 - $44.19 $5.48 Million - $7.73 Million
175,000 New
175,000 $7.37 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Senator Investment Group LP Portfolio

Follow Senator Investment Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Senator Investment Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Senator Investment Group LP with notifications on news.